Q1 Earnings Forecast for AURA Issued By HC Wainwright

Aura Biosciences, Inc. (NASDAQ:AURA) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Aura Biosciences in a research note issued on Thursday, November 13th. HC Wainwright analyst A. Maldonado forecasts that the company will earn ($0.44) per share for the quarter. HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Aura Biosciences’ Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.45) EPS and Q4 2026 earnings at ($0.45) EPS.

AURA has been the topic of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aura Biosciences in a report on Tuesday, November 11th. Zacks Research upgraded Aura Biosciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $20.50.

Aura Biosciences Stock Performance

Shares of AURA stock opened at $5.53 on Monday. Aura Biosciences has a 52 week low of $4.34 and a 52 week high of $10.16. The firm’s 50-day simple moving average is $6.01 and its two-hundred day simple moving average is $6.23. The firm has a market cap of $351.16 million, a price-to-earnings ratio of -2.85 and a beta of 0.45.

Aura Biosciences (NASDAQ:AURA) last released its earnings results on Thursday, November 13th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.06.

Insider Transactions at Aura Biosciences

In other news, insider Los Pinos Elisabet De sold 9,049 shares of the company’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $6.35, for a total transaction of $57,461.15. Following the sale, the insider directly owned 474,391 shares in the company, valued at $3,012,382.85. This represents a 1.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CTO Mark Plavsic sold 12,169 shares of the stock in a transaction dated Thursday, October 16th. The stock was sold at an average price of $6.35, for a total transaction of $77,273.15. Following the completion of the sale, the chief technology officer directly owned 197,287 shares in the company, valued at approximately $1,252,772.45. The trade was a 5.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 22,114 shares of company stock valued at $140,424 in the last ninety days. Insiders own 6.30% of the company’s stock.

Institutional Trading of Aura Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of the company. Frazier Life Sciences Management L.P. bought a new position in Aura Biosciences in the 2nd quarter valued at $31,926,000. Nantahala Capital Management LLC raised its position in shares of Aura Biosciences by 67.1% in the second quarter. Nantahala Capital Management LLC now owns 2,117,697 shares of the company’s stock worth $13,257,000 after buying an additional 850,000 shares in the last quarter. Long Focus Capital Management LLC boosted its stake in Aura Biosciences by 30.8% during the first quarter. Long Focus Capital Management LLC now owns 3,319,582 shares of the company’s stock valued at $19,453,000 after buying an additional 781,808 shares during the period. Acorn Capital Advisors LLC purchased a new position in Aura Biosciences during the first quarter worth about $3,460,000. Finally, Vanguard Group Inc. increased its stake in Aura Biosciences by 16.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,890,503 shares of the company’s stock worth $17,863,000 after acquiring an additional 413,001 shares during the last quarter. 96.75% of the stock is currently owned by hedge funds and other institutional investors.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.